Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

Exclusion Criteria

• •1. Patients with severe primary respiratory diseases or other pathogenic microbial pneumonia that needs to be differentiated from COVID-19;
• •2. immune deficiency disease, or use of immunosuppressants or glucocorticoids in the last 3 months;
• •3. pregnant and lactating women;
• •4. People with allergic constitution (allergic to more than two drugs or food or known allergic to the drug used in this study);
• •5. mentally ill persons or persons without self-awareness;
• •6. Patients whose expected survival time from screening is not more than 48 hours; (7) those who have been intubated or mechanically ventilated at the time of screening;
• •(8) In patients with serious primary diseases of heart, brain, liver and kidney, ALT and AST were 1.5 times higher than the upper limit of normal value; (9) Other conditions that the investigator considers inappropriate for clinical trial participation.